Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

40.31 +2.19 (+5.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,509,217
Open 38.73
Bid (Size) 36.82 (100)
Ask (Size) 44.00 (100)
Prev. Close 38.12
Today's Range 38.50 - 40.35
52wk Range 28.66 - 117.33
Shares Outstanding 115,926,629
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Navan and Corcept Investors with Large Losses to Contact the Firm Before the Upcoming Lead Plaintiff Deadlines
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
+5.5%
+5.5%
1 Month
+12.1%
+12.1%
3 Month
-49.5%
-49.5%
6 Month
-52.0%
-52.0%
1 Year
-64.7%
-64.7%

More News

Read More
News headline image
Corcept Therapeutics Outperforms: How a Surprise FDA Approval Ignited a Late-March Rally
Via MarketMinute
Topics ETFs Intellectual Property Stocks
News headline image
Biotech Defies Gravity: Sarepta and Corcept Lead Midday Healthcare Rally Amidst Market Volatility
Via MarketMinute
Topics Economy Intellectual Property Stocks
News headline image
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
3 Reasons to Avoid CORT and 1 Stock to Buy Instead
Via StockStory
News headline image
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox
Via NewMediaWire
Topics Lawsuit
News headline image
Deadline is April 21, 2026 to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Contact Kaplan Fox
Via TheNewswire.com
Topics Lawsuit
News headline image
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week ↗
Via The Motley Fool
News headline image
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
CORCEPT THERAPEUTICS DEADLINE FOR LEADERSHIP is April 21, 2026 in a Securities Fraud Lawsuit - Investors Encouraged to Contact Kaplan Fox
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – CORT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Reminds Investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to a Securities Class Action Deadline - Contact Kaplan Fox Before April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough
Via MarketMinute
Topics Intellectual Property
News headline image
The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli
Via Finterra
Topics Economy Intellectual Property
News headline image
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT
From SkyMedia, LLC
Via GlobeNewswire
News headline image
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗
Via The Motley Fool
Wednesday's session: top gainers and losers ↗
Via Chartmill
News headline image
FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
What's Behind The Jump In Corcept Therapeutics Stock? ↗
Via Benzinga
News headline image
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
From Kahn Swick & Foti, LLC
Via GlobeNewswire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?
Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.
What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?
Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?
The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market
What is the current price of Corcept Therapeutics Incorporated - Common Stock?
The current price of Corcept Therapeutics Incorporated - Common Stock is 40.31
When was Corcept Therapeutics Incorporated - Common Stock last traded?
The last trade of Corcept Therapeutics Incorporated - Common Stock was at 03/31/26 04:00 PM ET
What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?
The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 4.67B
How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?
Corcept Therapeutics Incorporated - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.